BeyondSpring Files 2023 Annual Report on Form 20-F
BYSI Stock | USD 1.77 0.03 1.72% |
Under 60% of all BeyondSpring's traders are looking to take a long position. The analysis of the overall investor sentiment regarding BeyondSpring suggests that some traders are interested. BeyondSpring's investing sentiment shows overall attitude of investors towards BeyondSpring.
BeyondSpring |
FLORHAM PARK, N.J., April 29, 2024 -- BeyondSpring Inc. , a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission on April 29, 2024. The annual report on Form 20-F, which contains the Companys audited consolidated financial
Read at finance.yahoo.com
BeyondSpring Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BeyondSpring can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BeyondSpring Fundamental Analysis
We analyze BeyondSpring's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeyondSpring using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeyondSpring based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
BeyondSpring is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
BeyondSpring Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeyondSpring stock to make a market-neutral strategy. Peer analysis of BeyondSpring could also be used in its relative valuation, which is a method of valuing BeyondSpring by comparing valuation metrics with similar companies.
Peers
BeyondSpring Related Equities
ADTX | Aditxt | 17.65 | ||||
MCRB | Seres Therapeutics | 15.58 | ||||
EYPT | Eyepoint Pharmaceuticals | 3.13 | ||||
SCPH | Scpharmaceuticals | 1.79 | ||||
ARMP | Armata Pharmaceuticals | 1.78 | ||||
INKT | Mink Therapeutics | 1.47 | ||||
PLX | Protalix Biotherapeutics | 1.18 | ||||
RVPH | Reviva Pharmaceuticals | 0.88 | ||||
MIST | Milestone Pharmaceuticals | 0.54 | ||||
FBRX | Forte Biosciences | 0.50 | ||||
SRZN | Surrozen | 0.66 | ||||
ONCY | Oncolytics Biotech | 1.05 | ||||
KTTA | Pasithea Therapeutics | 1.61 | ||||
ALVR | Allovir | 3.51 | ||||
CADL | Candel Therapeutics | 3.97 | ||||
SLS | Sellas Life | 4.10 | ||||
KA | Kineta | 7.69 | ||||
ONCT | Oncternal Therapeutics | 37.72 |
Complementary Tools for BeyondSpring Stock analysis
When running BeyondSpring's price analysis, check to measure BeyondSpring's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeyondSpring is operating at the current time. Most of BeyondSpring's value examination focuses on studying past and present price action to predict the probability of BeyondSpring's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeyondSpring's price. Additionally, you may evaluate how the addition of BeyondSpring to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |